{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T04:23:28Z","timestamp":1742358208727,"version":"3.40.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,18]]},"DOI":"10.7759\/cureus.80758","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T10:26:28Z","timestamp":1742293588000},"source":"Crossref","is-referenced-by-count":0,"title":["The Complexities of Managing Acute Coronary Syndrome in a Patient With Hereditary Hemorrhagic Telangiectasia: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Parisa","family":"Aijaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafi","family":"Aibani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Mnuskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200009283431305","article-title":"Liver disease in patients with hereditary hemorrhagic telangiectasia","volume":"343","author":"Garcia-Tsao G","year":"2000","unstructured":"Garcia-Tsao G, Korzenik JR, Young L, et al.. Liver disease in patients with hereditary hemorrhagic telangiectasia. N Engl J Med. 2000, 343:931-6. 10.1056\/NEJM200009283431305","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2022.09.003","article-title":"Safety, tolerability, and effectiveness of anticoagulation and antiplatelet therapy in hereditary hemorrhagic telangiectasia","volume":"21","author":"Virk ZM","year":"2023","unstructured":"Virk ZM, Zhang E, Rodriguez-Lopez J, et al.. Safety, tolerability, and effectiveness of anticoagulation and antiplatelet therapy in hereditary hemorrhagic telangiectasia. J Thromb Haemost. 2023, 21:26-36. 10.1016\/j.jtha.2022.09.003","journal-title":"J Thromb Haemost"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1281-4","article-title":"Future treatments for hereditary hemorrhagic telangiectasia","volume":"15","author":"Robert F","year":"2020","unstructured":"Robert F, Desroches-Castan A, Bailly S, Dupuis-Girod S, Feige JJ. Future treatments for hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis. 2020, 15:4. 10.1186\/s13023-019-1281-4","journal-title":"Orphanet J Rare Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v3.i4.330","article-title":"Bleeding and clotting in hereditary hemorrhagic telangiectasia","volume":"3","author":"Dittus C","year":"2015","unstructured":"Dittus C, Streiff M, Ansell J. Bleeding and clotting in hereditary hemorrhagic telangiectasia. World J Clin Cases. 2015, 3:330-7. 10.12998\/wjcc.v3.i4.330","journal-title":"World J Clin Cases"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4065\/84.10.917","article-title":"Acute coronary syndromes: diagnosis and management, part I","volume":"84","author":"Kumar A","year":"2009","unstructured":"Kumar A, Cannon CP. Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc. 2009, 84:917-38. 10.4065\/84.10.917","journal-title":"Mayo Clin Proc"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/ng1294-345","article-title":"Endoglin, a TGF-\u03b2 binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1","volume":"8","author":"McAllister KA","year":"1994","unstructured":"McAllister KA, Grogg KM, Johnson DW, et al.. Endoglin, a TGF-\u03b2 binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet. 1994, 8:345-51. 10.1038\/ng1294-345","journal-title":"Nat Genet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/ng0696-189","article-title":"Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2","volume":"13","author":"Johnson DW","year":"1996","unstructured":"Johnson DW, Berg JN, Baldwin MA, et al.. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet. 1996, 13:189-95. 10.1038\/ng0696-189","journal-title":"Nat Genet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.04.006","article-title":"Reported cardiac phenotypes in hereditary hemorrhagic telangiectasia emphasize burdens from arrhythmias, anemia and its treatments, but suggest reduced rates of myocardial infarction","volume":"215","author":"Shovlin CL","year":"2016","unstructured":"Shovlin CL, Awan I, Cahilog Z, Abdulla FN, Guttmacher AE. Reported cardiac phenotypes in hereditary hemorrhagic telangiectasia emphasize burdens from arrhythmias, anemia and its treatments, but suggest reduced rates of myocardial infarction. Int J Cardiol. 2016, 215:179-85. 10.1016\/j.ijcard.2016.04.006","journal-title":"Int J Cardiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.09.011","article-title":"2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"77","author":"Kumbhani DJ","year":"2021","unstructured":"Kumbhani DJ, Cannon CP, Beavers CJ, et al.. 2020 ACC expert consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021, 77:629-58. 10.1016\/j.jacc.2020.09.011","journal-title":"J Am Coll Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7326\/M20-1443","article-title":"Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia","volume":"173","author":"Faughnan ME","year":"2020","unstructured":"Faughnan ME, Mager JJ, Hetts SW, et al.. Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia. Ann Intern Med. 2020, 173:989-1001. 10.7326\/M20-1443","journal-title":"Ann Intern Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.29352","article-title":"Utility of the dual antiplatelet therapy score to guide antiplatelet therapy: a systematic review and meta-analysis","volume":"97","author":"Mihatov N","year":"2021","unstructured":"Mihatov N, Secemsky EA, Kereiakes DJ, et al.. Utility of the dual antiplatelet therapy score to guide antiplatelet therapy: a systematic review and meta-analysis. Catheter Cardiovasc Interv. 2021, 97:569-78. 10.1002\/ccd.29352","journal-title":"Catheter Cardiovasc Interv"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1179-1","article-title":"Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia","volume":"14","author":"Shovlin CL","year":"2019","unstructured":"Shovlin CL, Millar CM, Droege F, et al.. Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis. 2019, 14:210. 10.1186\/s13023-019-1179-1","journal-title":"Orphanet J Rare Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2013.04.052","article-title":"Angina pectoris or myocardial infarctions, pulmonary arteriovenous malformations, hereditary hemorrhagic telangiectasia, and paradoxical emboli","volume":"112","author":"Clark K","year":"2013","unstructured":"Clark K, Pyeritz RE, Trerotola SO. Angina pectoris or myocardial infarctions, pulmonary arteriovenous malformations, hereditary hemorrhagic telangiectasia, and paradoxical emboli. Am J Cardiol. 2013, 112:731-4. 10.1016\/j.amjcard.2013.04.052","journal-title":"Am J Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2005.074013","article-title":"Spontaneous dissection of the left main coronary artery in a patient with Osler-Weber-Rendu disease","volume":"92","author":"Mieghem CA","year":"2006","unstructured":"Mieghem CA, Ligthart JM, Cademartiri F. Spontaneous dissection of the left main coronary artery in a patient with Osler-Weber-Rendu disease. Heart. 2006, 92:394. 10.1136\/hrt.2005.074013","journal-title":"Heart"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcl017","article-title":"Myocardial infarction in a patient with normal coronary arteries and hereditary haemorrhagic telangiectasia","volume":"99","author":"Talha S","year":"2006","unstructured":"Talha S, Brandt C, Maamari G, Mossard JM, Germain P, Andres E. Myocardial infarction in a patient with normal coronary arteries and hereditary haemorrhagic telangiectasia. QJM. 2006, 99:195-6. 10.1093\/qjmed\/hcl017","journal-title":"QJM"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.rec.2017.10.010","article-title":"Coronary angiography and interventions in patients with hereditary hemorrhagic telangiectasia","volume":"71","author":"Triantafyllis AS","year":"2018","unstructured":"Triantafyllis AS, Kalogeropoulos AS, McCutcheon K, Desmet W, Bennett J. Coronary angiography and interventions in patients with hereditary hemorrhagic telangiectasia. Rev Esp Cardiol (Engl Ed). 2018, 71:1079-81. 10.1016\/j.rec.2017.10.010","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2015.00034","article-title":"Contribution of oxidative stress to endothelial dysfunction in hereditary hemorrhagic telangiectasia","volume":"6","author":"Jerkic M","year":"2015","unstructured":"Jerkic M, Letarte M. Contribution of oxidative stress to endothelial dysfunction in hereditary hemorrhagic telangiectasia. Front Genet. 2015, 6:34. 10.3389\/fgene.2015.00034","journal-title":"Front Genet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3121\/cmr.4.1.66","article-title":"Hereditary hemorrhagic telangiectasia, a vascular dysplasia affecting the TGF-\u03b2 signaling pathway","volume":"4","author":"Fern\u00e1ndez-L A","year":"2006","unstructured":"Fern\u00e1ndez-L A, Sanz-Rodriguez F, Blanco FJ, Bernab\u00e9u C, Botella LM. Hereditary hemorrhagic telangiectasia, a vascular dysplasia affecting the TGF-\u03b2 signaling pathway. Clin Med Res. 2006, 4:66-78. 10.3121\/cmr.4.1.66","journal-title":"Clin Med Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/334825-the-complexities-of-managing-acute-coronary-syndrome-in-a-patient-with-hereditary-hemorrhagic-telangiectasia-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T10:26:30Z","timestamp":1742293590000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/334825-the-complexities-of-managing-acute-coronary-syndrome-in-a-patient-with-hereditary-hemorrhagic-telangiectasia-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.80758","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,18]]}}}